Literature DB >> 17198767

Current guidelines and standards of practice for restless legs syndrome.

Wayne A Hening1.   

Abstract

Algorithms for treatment of restless legs syndrome (RLS) include both nonpharmacologic and pharmacologic therapy. Patients with RLS are divided into 3 groups: (1) those with intermittent RLS symptoms; (2) those with daily RLS symptoms; and (3) those whose symptoms are refractory to standard treatments. Many patients do not require medication, and symptoms often can be relieved with good sleep hygiene and avoidance of medications and factors that provoke symptoms. Recent large-scale clinical trials have proved the efficacy of therapy for RLS when it is required. Several classes of medications are helpful, but dopaminergic therapy appears to be most effective and relieves symptoms rapidly. The first step in managing RLS is to ensure that there is an adequate diagnosis; this involves discriminating RLS from other conditions that may share a number of features. Finally, it is important to tailor treatment to the needs of each individual patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17198767     DOI: 10.1016/j.amjmed.2006.11.004

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

1.  To what extent and why are COPD and Willis-Ekbom disease associated?

Authors:  Tugba Mandal; Şenay Aydın; Dilek Kanmaz; Ahmet Levent Karasulu; Gülfidan Aras; Esin Tuncay
Journal:  Sleep Breath       Date:  2016-05-30       Impact factor: 2.816

2.  Effect of sensory stimuli on restless legs syndrome: a randomized crossover study.

Authors:  Anouk D Rozeman; Truus Ottolini; Diana C Grootendorst; Oscar J M Vogels; Roselyne M Rijsman
Journal:  J Clin Sleep Med       Date:  2014-08-15       Impact factor: 4.062

Review 3.  Strategies for the treatment of restless legs syndrome.

Authors:  Mark J Buchfuhrer
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

4.  Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome.

Authors:  Diego Garcia-Borreguero; Jeffrey Patrick; Sarah DuBrava; Philip M Becker; Alan Lankford; Crystal Chen; Jeffrey Miceli; Lloyd Knapp; Richard P Allen
Journal:  Sleep       Date:  2014-04-01       Impact factor: 5.849

5.  Restless legs syndrome in a primary contact setting: a case report.

Authors:  Maja Stupar
Journal:  J Can Chiropr Assoc       Date:  2008-06

6.  Update on the management of restless legs syndrome: existing and emerging treatment options.

Authors:  Maurizio F Facheris; Andrew A Hicks; Peter P Pramstaller; Irene Pichler
Journal:  Nat Sci Sleep       Date:  2010-09-08

7.  Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch.

Authors:  Birgit Högl; Wolfgang H Oertel; Karin Stiasny-Kolster; Peter Geisler; Heike Beneš; Diego García-Borreguero; Claudia Trenkwalder; Werner Poewe; Erwin Schollmayer; Ralf Kohnen
Journal:  BMC Neurol       Date:  2010-09-28       Impact factor: 2.474

8.  Nondrug-related aspect of treating Ekbom disease, formerly known as restless legs syndrome.

Authors:  Ulrike H Mitchell
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-06       Impact factor: 2.570

Review 9.  Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose?

Authors:  Akito Kume
Journal:  Neuropsychiatr Dis Treat       Date:  2014-02-03       Impact factor: 2.570

10.  Haplotype Association of the MAP2K5 Gene with Antipsychotics-Induced Symptoms of Restless Legs Syndrome among Patients with Schizophrenia.

Authors:  Seung-Gul Kang; Yu Jin Lee; Young-Min Park; Leen Kim; Heon-Jeong Lee
Journal:  Psychiatry Investig       Date:  2018-01-16       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.